Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Jan 28, 2009; 15(4): 449-456
Published online Jan 28, 2009. doi: 10.3748/wjg.15.449
Published online Jan 28, 2009. doi: 10.3748/wjg.15.449
Table 4 Second-line therapies
| Treatment group | ||
| CAPIRI (n = 17) number (%) patients | CAPIRI-Bev (n = 29) number (%) patients | |
| Folfiri + Bevacizumab | - | 4 (14) |
| Irinotecan + Cetuximab | - | 1 (3) |
| Capox +/-Bevacizumab | 1 (6) | 2 (7) |
| Capox + Cetuximab | - | 1 (3) |
| Folfox +/- Cetuximab | 2 (12) | 2 (7) |
| Cetuximab alone | 1 (6) | 1 (3) |
| Capiri +/- Cetuximab | - | 4 (14) |
| Capiri + Bevacizumab | 1 (6) | - |
| No second line | 10 (59) | 14 (48) |
- Citation: Moehler M, Sprinzl MF, Abdelfattah M, Schimanski CC, Adami B, Godderz W, Majer K, Flieger D, Teufel A, Siebler J, Hoehler T, Galle PR, Kanzler S. Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. World J Gastroenterol 2009; 15(4): 449-456
- URL: https://www.wjgnet.com/1007-9327/full/v15/i4/449.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.449